Table of Contents Author Guidelines Submit a Manuscript
Journal of Obesity
Volume 2011, Article ID 898013, 6 pages
http://dx.doi.org/10.1155/2011/898013
Research Article

Switching to Aripiprazole as a Strategy for Weight Reduction: A Meta-Analysis in Patients Suffering from Schizophrenia

Abarbanel Mental Health Center and Geha Mental Health Center Affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Bat-Yam 59100, Israel

Received 17 April 2010; Revised 15 July 2010; Accepted 28 July 2010

Academic Editor: S. B. Heymsfield

Copyright © 2011 Yoram Barak and Dov Aizenberg. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Faulkner, T. Cohn, and G. Remington, “Interventions to reduce weight gain in schizophrenia,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD005148, 2007. View at Google Scholar · View at Scopus
  2. H. A. Nasrallah, “Metabolic findings from the CATIE trial and their relation to tolerability,” CNS Spectrums, vol. 11, no. 7, supplement 7, pp. 32–39, 2006. View at Google Scholar · View at Scopus
  3. T. Baptista, Y. ElFakih, E. Uzcátegui, I. Sandia, E. Tálamo, E. Araujo De Baptista, and S. Beaulieu, “Pharmacological management of atypical antipsychotic-induced weight gain,” CNS Drugs, vol. 22, no. 6, pp. 477–495, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. R. W. Buchanan, J. Kreyenbuhl, and J. Kreyenbuhl, “The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements,” Schizophrenia Bulletin, vol. 36, no. 1, pp. 71–93, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. M. Weber, A. M. Gutierrez, and M. Mohammadi, “The risks and benefits of switching antipsychotics: a case study approach,” Perspectives in Psychiatric Care, vol. 45, no. 1, pp. 54–61, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. D. I. Brixner, Q. Said, P. K. Corey-Lisle, A. V. Tuomari, G. J. L'Italien, W. Stockdale, and G. M. Oderda, “Naturalistic impact of second-generation antipsychotics on weight gain,” Annals of Pharmacotherapy, vol. 40, no. 4, pp. 626–632, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. S. Gentile, “A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole,” Neuropsychiatric Disease and Treatment, vol. 5, no. 1, pp. 117–125, 2009. View at Google Scholar · View at Scopus
  8. C.-U. Pae, “A review of the safety and tolerability of aripiprazole,” Expert Opinion on Drug Safety, vol. 8, no. 3, pp. 373–386, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. K. Komossa, C. Rummel-Kluge, and C. Rummel-Kluge, “Aripiprazole versus other atypical antipsychotics for schizophrenia,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD006569, 2009. View at Google Scholar
  10. S. H. Downs and N. Black, “The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions,” Journal of Epidemiology and Community Health, vol. 52, no. 6, pp. 377–384, 1998. View at Google Scholar · View at Scopus
  11. T. A. Pigott, W. H. Carson, A. R. Saha, A. F. Torbeyns, E. G. Stock, and G. G. Ingenito, “Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study,” Journal of Clinical Psychiatry, vol. 64, no. 9, pp. 1048–1056, 2003. View at Google Scholar · View at Scopus
  12. D. E. Casey, W. H. Carson, A. R. Saha, A. Liebeskind, M. W. Ali, D. Jody, and G. G. Ingenito, “Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study,” Psychopharmacology, vol. 166, no. 4, pp. 391–399, 2003. View at Google Scholar · View at Scopus
  13. B. Chavez and R. A. Poveda, “Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances,” Annals of Pharmacotherapy, vol. 40, no. 12, pp. 2265–2268, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. S.-K. Lin and C.-K. Chen, “Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: a case report,” Journal of Clinical Psychiatry, vol. 67, no. 8, p. 1307, 2006. View at Google Scholar · View at Scopus
  15. R. D. Spurling, J. S. Lamberti, D. Olsen, X. Tu, and W. Tang, “Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review,” Journal of Clinical Psychiatry, vol. 68, no. 3, pp. 406–409, 2007. View at Google Scholar · View at Scopus
  16. S. H. Kim, O. Ivanova, F. A. Abbasi, C. A. Lamendola, G. M. Reaven, and I. D. Glick, “Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study,” Journal of Clinical Psychopharmacology, vol. 27, no. 4, pp. 365–368, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. S. G. Schorr, C. J. Slooff, R. Postema, W. Van Oven, M. Schilthuis, R. Bruggeman, and K. Taxis, “A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole,” Acta Psychiatrica Scandinavica, vol. 118, no. 3, pp. 246–250, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. J. W. Newcomer, J. A. Campos, and J. A. Campos, “A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine,” Journal of Clinical Psychiatry, vol. 69, no. 7, pp. 1046–1056, 2008. View at Google Scholar · View at Scopus
  19. C.-U. Pae, A. Serretti, and A. Serretti, “Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study,” European Neuropsychopharmacology, vol. 19, no. 8, pp. 562–570, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. S.-W. Kim, I.-S. Shin, J.-M. Kim, J.-H. Lee, Y.-H. Lee, S.-J. Yang, and J.-S. Yoon, “Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia,” Clinical Neuropharmacology, vol. 32, no. 5, pp. 243–249, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. H. Takeuchi, H. Uchida, T. Suzuki, K. Watanabe, and H. Kashima, “Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study,” Psychiatry and Clinical Neurosciences, vol. 64, no. 1, pp. 104–106, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. T. J. R. Lambert, “Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder,” Evidence-Based Mental Health, vol. 12, no. 2, p. 50, 2009. View at Publisher · View at Google Scholar · View at PubMed
  23. J. M. Kane, O. Osuntokun, L. A. Kryzhanovskaya, W. Xu, V. L. Stauffer, S. B. Watson, and A. Breier, “A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia,” Journal of Clinical Psychiatry, vol. 70, no. 4, pp. 572–581, 2009. View at Publisher · View at Google Scholar
  24. R. Tandon, R. N. Marcus, and R. N. Marcus, “A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA),” Schizophrenia Research, vol. 84, no. 1, pp. 77–89, 2006. View at Publisher · View at Google Scholar · View at PubMed
  25. J. Wolf, F. Janssen, and F. Janssen, “A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA),” Current Medical Research and Opinion, vol. 23, no. 10, pp. 2313–2323, 2007. View at Publisher · View at Google Scholar · View at PubMed
  26. W. Deberdt, A. Winokur, and A. Winokur, “Amantadine for weight gain associated with olanzapine treatment,” European Neuropsychopharmacology, vol. 15, no. 1, pp. 13–21, 2005. View at Publisher · View at Google Scholar · View at PubMed
  27. C. Y. Kim, S. Chung, and S. Chung, “A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder,” International Clinical Psychopharmacology, vol. 24, no. 4, pp. 181–188, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. P. J. Weiden, “Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia,” Journal of Clinical Psychiatry, vol. 68, supplement 4, pp. 34–39, 2007. View at Google Scholar · View at Scopus